現代牙科(03600.HK)越南廠房料年底投產 未來積極考慮增派息
現代牙科(03600.HK)財務總監關毅傑在記者會表示,旗下越南新廠房計劃於年底生產,雖然行業無關稅影響,但考慮到政治敏感,故決定在當地建廠,投資額約1,000萬元,相信可為集團帶來長遠多一個低成本的義齒生產線,暫時目標200-300人,因生產成本中50% 是人工,而越南人工是中國一半,故當地生產有助成本降低。
他指,越南廠房會先服務美國市場,未來可能會將部份海外訂單生產轉至當地。
他提到,至去年底,集團持有約7億元現金,除考慮回購外,管理層亦積極考慮增派息,以及增加併購,疫情下可購買資產更多,但公司選擇收購對象時會更多考慮策略性需要和協同,如未進入市場或目前牙醫界所需產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.